At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
02696 HENLIUS
Closed 04-09 16:08:13
80.000
+0.750
+0.95%
High80.450
Low77.300
Vol1.10M
Open79.600
D1 Closing79.250
Amplitude3.97%
Mkt Cap43.44B
Tradable Cap27.69B
Total Shares543.00M
T/O87.45M
T/O Rate0.32%
Tradable Shares346.07M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Loading ...
Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
HENLIUS Wins NMPA Nod to Broaden Hanlikang’s Rituximab Label for Two DLBCL Regimens
Shanghai Henlius Biotech doses first patient in Phase 1b/2 HLX701 combo trial for advanced colorectal cancer in Chinese mainland; study compares HLX701 plus cetuximab and FOLFOX/FOLFIRI versus placebo combo
Shanghai Henlius Biotech Inc is a China-based company principally engaged in biopharmaceutical research and development, biopharmaceutical services and biopharmaceutical production and sales. The Company’s main products include HANQUYOU (trastuzumab for injection), HANNAIJIA (neratinib maleate), HANSIZHUANG (serplulimab injection), HANLIKANG (rituximab injection), HANDAYUAN (adalimumab injection), HANBEITAI (bevacizumab injection) and others. The Company’s products are mainly used in the treatment of adjuvant breast cancer, metastatic breast cancer, metastatic gastric cancer, metastatic non-squamous non-small cell lung cancer, polyarticular juvenile idiopathic arthritis and others. The Company mainly operates its businesses in the domestic and overseas markets.